January 27, 2012: Astex Pharmaceuticals has announced that the the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc and GlaxoSmithKline (GSK) in 2009 is terminating and existing research work and assets generated under the CLIMB™ epigenetic collaboration will be transferred to GSK. Astex will have no further obligation to conduct additional research work on the programme. The decision follows on from the review and rationalisation of Astex’s internal pipeline and drug discovery programmes as part of the recent merger of Astex Therapeutics Limited and SuperGen to form Astex Pharmaceuticals, Inc. Astex will continue to be eligible to receive milestones and royalties under an asset transfer agreement. A separate R&D collaboration and licence agreement that includes a multi-target drug discovery collaboration entered into by Astex Therapeutics Limited and GSK in November 2009 will continue as previously announced.
Astex Pharmaceuticals is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with pharmaceutical companies. The company has developed Dacogen® (decitabine) for Injection and receives royalties on global sales.
- RSS Feed
